Aptose Reports Results for the Second Quarter 2022
August 02, 2022 16:01 ET
|
Aptose Biosciences, Inc.
─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete Remissions and Safety Across Three Dose Levels...
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 27, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
July 19, 2022 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
June 27, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
June 02, 2022 20:10 ET
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 ...
Aptose Presents Highlights from Corporate Update and KOL Event
June 02, 2022 17:30 ET
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
May 31, 2022 16:15 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
May 25, 2022 08:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
May 12, 2022 10:00 ET
|
Aptose Biosciences, Inc.
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) --...
Aptose Reports Results for the First Quarter 2022
May 09, 2022 16:01 ET
|
Aptose Biosciences, Inc.
Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) --...